Gemcitabine.
There is widespread consensus that a plateau has been reached in the effectiveness of known DNA interactive drugs against most malignancies. Combination treatments, dose intensification and schedule alterations (e.g. infusional and neoadjuvant treatments) represent exciting research opportunities and possibly the means for making meaningful progress. However, frustration with the slow pace of even these most novel approaches has led to a search for newer drug targets and great expectations of new drugs.
Prendiville
J
J
Department of Medicine, Royal Marsden Hospital, Sutton, Surrey.
O'Brien
M
M
D000964:Antimetabolites, Antineoplastic / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D019384:Nucleic Acid Synthesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D019384:Nucleic Acid Synthesis Inhibitors; D003841:Deoxycytidine; D004247:DNA; D002945:Cisplatin; D000093542:Gemcitabine